Skip to main content
2033 search results for:

Fulvestrant 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Fulvestrant | News

    Fulvestrant/palbociclib

    Drug-induced interstitial lung disease and drug ineffective
  2. 01-12-2023 | Fulvestrant | News

    Fulvestrant/palbociclib

    Heart failure with reduced ejection fraction
  3. 01-08-2023 | Lichen Sclerosus Et Atrophicus | News

    Fulvestrant/palbociclib

    Extragenital lichen sclerosus: case report
  4. Open Access 04-11-2023 | Breast Cancer | OriginalPaper

    Palbociclib sensitizes ER-positive breast cancer cells to fulvestrant by promoting the ubiquitin-mediated degradation of ER-α via SNHG17/Hippo-YAP axis

    Breast cancer is one of the top main reasons for cancer-related mortality in females, and its incidence and mortality are also very high in China [ 1 , 2 ]. Triple-negative breast cancer (TNBC) is immunohistochemically characterized by lacking gene …

  5. 01-06-2023 | Breast Cancer | News

    Fulvestrant

    Nicolau Syndrome: case report
  6. 01-06-2023 | Pancreatectomy | News

    Fulvestrant/ribociclib

    Lack of efficacy: case report
  7. 25-10-2023 | Breast Cancer | OriginalPaper

    Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

    Prolonged overall survival (OS) with preserved quality of life (QOL) is the goal of advanced or metastatic breast cancer (ABC) treatment [ 1 ]. Moreover, the extent of disease, age, disease-free interval, hormone receptor (HR) status, and other …

  8. Open Access 31-03-2023 | Breast Cancer | OriginalPaper

    Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial)

    The aim of advanced breast cancer (ABC) treatment is prolonged overall survival (OS) while maintaining the patient’s quality of life (QOL) [ 1 ]. ABC treatment has become increasingly complex owing to multiple newly approved drugs for the treatment …

  9. 17-11-2023 | Fulvestrant | OriginalPaper

    Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?

    Breast cancer is the most common neoplasm in US women, excluding non-melanoma skin cancers, and the second leading cause of cancer-related death after lung cancer, yielding a significant burden on the US economy [ 1 ]. The incidence and mortality …

  10. 01-01-2023 | Cerebral Sinus Venous Thrombosis | News

    Fulvestrant/letrozole/ribociclib

    Thromboembolic events: 6 case reports
  11. 01-01-2023 | Esophagitis | News

    Fulvestrant/palbociclib/zoledronic acid

    Erosive-oesophagitis: case report
  12. 01-11-2022 | Fulvestrant | News

    Fulvestrant/letrozole/palbociclib

    Lack of efficacy: 14 case reports
  13. Open Access 15-06-2023 | Breast Cancer | OriginalPaper

    Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

    Metastatic Hormone Receptor-positive (HR+) breast cancer remains the predominant cause of breast cancer mortality in women, despite advances in targeted therapies [ 1 ]. Breast cancers expressing Estrogen Receptor alpha (ERα, encoded by the ESR1 …

  14. 01-07-2022 | Breast Cancer | News

    Fulvestrant/palbociclib

    Lack of efficacy: case report
  15. 01-07-2022 | Trastuzumab | News

    Fulvestrant

    Lack of efficacy: case report
  16. Open Access 01-12-2023 | Breast Cancer | OriginalPaper

    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

    The addition of CDK4/6 inhibitors (CDK4/6is) to endocrine therapy (ET) has greatly improved outcomes for patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC) [ 1 ].

  17. Open Access 01-12-2023 | Breast Cancer | OriginalPaper

    PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

    Despite adjuvant therapy improvements in HR + /HER2 − breast cancer, a substantial proportion of patients still progresses to the metastatic stage. In the metastatic setting, when planning a therapy or therapy sequence, the focus is not only on …

  18. Open Access 01-12-2022 | Metastasis | OriginalPaper

    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

    Breast cancer is the most common cancer among women and the second most frequent newly diagnosed cancer worldwide [ 1 ]. Breast cancer has been divided into subtypes depending on the presence of hormone receptors (HRs) for estrogen and progesterone …

  19. 01-08-2021 | Bullous Pemphigoid | News

    Fulvestrant/letrozole/palbociclib

    Cutaneous reactions: 11 case reports
  20. 01-01-2021 | Joint Pain | News

    Fulvestrant

    Various toxicities: 4 case reports

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.